Advtmm2-transduced dendritic cell vaccine
Advtmm2-transduced dendritic cell vaccine - a cell-based cancer vaccine composed of autologous dendritic cells (dcs) transduced with a recombinant adenoviral vector encoding three full length human melanoma associated antigens (maas), tyrosinase, melan-a (mart-1) and the melanoma antigen a6 (magea6), with potential antineoplastic activity. Upon intradermal administration, adenovirus encoding tyrosinase/mart-1/magea6-transduced autologous dc vaccine may stimulate a cytotoxic t lymphocyte (ctl) response against tyrosinase/mart-1/magea6-positive tumor cells, which may result in tumor cell death and decreased tumor growth. Tyrosinase, a melanoma-specific differentiation antigen, catalyzes the first step of melanin synthesis in melanocytes. Vaccination with multi-antigen modified dc may improve the efficacy of the dc immunotherapy. Also see adenovirus encoding tyrosinase/mart-1/magea6-transduced autologous dendritic cell vaccine
Up to date info
Latest research - Advtmm2-transduced dendritic cell vaccine
|This medical article is a stub. You can help WikiMD by expanding it.|
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on Advtmm2-transduced dendritic cell vaccine for any updates.